QIAGEN Gaithersburg, Inc
A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19 infection. This study will evaluate the NeuMoDx SARS-CoV-2 Assay's clinical performance on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems.
SARS-CoV-2 Acute Respiratory Disease
NeuMoDx SARS-CoV-2 Assay
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 1432 participants |
Official Title : | Multi-Center Clinical Performance Evaluation of the NeuMoDx SARS-CoV-2 Assay on the NeuMoDx Molecular Systems |
Actual Study Start Date : | 2024-02-06 |
Estimated Primary Completion Date : | 2024-09-01 |
Estimated Study Completion Date : | 2024-09-01 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
QIAGEN Gaithersburg, Inc
Manchester, United Kingdom, M130BH